ADReCS

Pharmaceutical Information

Drug Name	Rasagiline
Drug ID	BADD_D02441
Description	Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indications and Usage	For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Marketing Status	approved
ATC Code	N04BD02
DrugBank ID	DB01367
KEGG ID	D08469; D10829
MeSH ID	C031967
PubChem ID	3052776
TTD Drug ID	D06OMW
NDC Product Code	16714-770; 0093-3061; 67877-260; 47781-683; 42291-780; 67877-259; 16714-771; 0093-3060; 42571-221; 47781-690; 42571-220; 42291-779
UNII	003N66TS6T
Synonyms	rasagiline \| N-2-propynyl-1-indanamine \| AGN 1135 \| AGN-1135 \| TVP 1022 \| TVP1022 \| TVP-1022 \| N-propargyl-1-aminoindan mesylate \| rasagiline hydrochloride \| TVP 101 \| TVP-101 \| 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride \| Azilect

Chemical Information

Molecular Formula	C12H13N
CAS Registry Number	136236-51-6
SMILES	C#CCNC1CCC2=CC=CC=C12
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Presyncope	02.11.04.013; 17.02.05.009; 24.06.02.010	0.003572%
Psychomotor hyperactivity	17.01.02.011; 19.11.02.003	0.004384%		-
Raynaud's phenomenon	24.04.03.003	0.001624%		-
Respiratory depression	17.02.05.047; 22.02.01.010	0.001624%		-
Restlessness	17.02.05.021; 19.11.02.002	0.001624%
Rhabdomyolysis	15.05.05.002	0.002436%
Seizure	17.12.03.001	0.005683%
Serotonin syndrome	12.03.01.041; 15.05.04.016; 17.05.02.004	0.014938%		-
Sleep attacks	19.02.02.005	0.002436%		-
Sleep disorder	19.02.04.001	0.003572%		-
Somnolence	17.02.04.006; 19.02.05.003	0.021596%
Speech disorder	17.02.08.003; 19.19.02.002; 22.12.03.027	0.005196%		-
Subarachnoid haemorrhage	12.01.10.011; 17.08.01.010; 24.07.04.004	0.004871%		-
Sudden death	02.03.04.013; 08.04.01.003	0.001624%
Syncope	02.11.04.015; 17.02.04.008; 24.06.02.012	0.012178%
Tachycardia	02.03.02.007	0.002436%		-
Transient ischaemic attack	17.08.04.001; 24.04.06.005	0.001624%
Tremor	17.01.06.002	0.013152%
Vertigo	04.04.01.003; 17.02.12.002	0.001624%
Withdrawal syndrome	08.06.02.012; 19.07.06.023	0.004384%		-
Mobility decreased	08.01.03.030; 15.03.05.023; 17.02.05.018	0.003247%		-
Musculoskeletal disorder	15.03.05.025	0.001624%		-
General physical health deterioration	08.01.03.018	0.006495%		-
Shock haemorrhagic	14.05.05.003; 24.06.02.014	0.004059%		-
Balance disorder	08.01.03.081; 17.02.02.007	0.005683%		-
Sudden onset of sleep	17.15.04.003	0.009742%		-
Dysstasia	08.01.03.089; 15.03.05.011; 17.02.02.012	0.002436%		-
Lower gastrointestinal haemorrhage	07.12.03.011; 24.07.02.030	0.001624%
Musculoskeletal stiffness	15.03.05.027	0.005196%		-
Depressive symptom	19.15.02.003	0.001624%		-

The 4th Page First Pre 4 5 6 Next Last Total 6 Pages